Results 161 to 170 of about 17,745 (243)

Two-layer energy scheduling of electrical and thermal smart grids with energy hubs including renewable and storage units considering energy markets. [PDF]

Sci Rep
Aich W, Basem A, Sawaran Singh NS, Mausam K, Hussein ZA, Dixit S, Ali NB, Said LB, Rajhi W, Mostafazadeh L.   +9 more
europepmc   +1 more source

Toracotomia em bloco em cães pré-medicados com acetilpromazina e anestesiados com tiopental sódico: efeitos sobre os gases sangüíneos e equilíbrio ácido-base [PDF]

, 1995
Amaury Regis de Moura, Sérgio Amaro Guimarães Fialho, Cláudio Corrêa Natalini, Daniel R. Stainki, Sônia Terezinha dos Anjos Lopes, Juan Thomás Wheeler   +5 more
openalex   +1 more source

Multi‐Objective Optimization of a Climate‐Responsive Green Hydrogen‐Based Multi‐Generation System with Advanced Energy Storage and Heat Recovery

Advanced Sustainable Systems, Volume 9, Issue 10, October 2025.
A novel hydrogen‐based multi‐generation system integrates CAES, PEME, and ORC for climate‐responsive power generation. Using response surface methodology, the system is optimized for energy efficiency, emissions, and cost. Results highlight its strong performance in temperate climates and its potential for modular, scalable deployment.
Ehsanolah Assareh, Mohtada Sadrzadeh, Nima Izadyar, Elmira Jamei, Saleh Mobayen, Mehrdad Ahmadinejad   +5 more
wiley   +1 more source

Assessing Extracellular Vesicle Turnover In Vivo Using Highly Sensitive Phosphatidylserine‐Binding Reagents

Advanced Science, Volume 12, Issue 40, October 27, 2025.
Extracellular vesicles (EVs) are promising biomarkers, but their heterogeneity limits clinical use. A novel high‐affinity phosphatidylserine (PS)‐binding reagent is introduced that reveals ≈90% of circulating EVs are PS⁺. This enables in vivo tracking, showing rapid EV clearance and retention in spleen immune cells—advancing EV quantification ...
Lavinia Flaskamp, Monica Prechtl, Annkathrin Scheck, Wenbo Hu, Christine Ried, Georg Kislinger, Mikael Simons, Anne B. Krug, Jan Kranich, Thomas Brocker   +9 more
wiley   +1 more source

A meta-analysis of risk factors for cardiovascular adverse events with anthracycline based chemotherapy in lymphoma patients. [PDF]

BMC Cancer
Dai B, Xu J, Wang B.
europepmc   +1 more source

Desvios porta-jugular e cava-jugular passivos em cães: Investigação de pressões sangüíneas

, 1999
Antônio Roberto Barros Coelho, Álvaro Antônio Bandeira Ferraz, Renato Dornelas Câmara Neto, Edmundo Machado Ferraz, Ayrton Ponce de Souza   +4 more
openalex   +1 more source

Genome‐Wide Insights and Polygenic Risk Scores in Common Epilepsies: A Narrative Review

American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, Volume 198, Issue 7, Page 76-87, October 2025.
ABSTRACT The research of single gene‐related disorders or pathogenic copy‐number variations (CNVs) has given a significant impetus to the shift from a diagnostic work‐up focused on epileptic syndromes to genomic approaches in individuals with severe pediatric‐onset epilepsies and in developmental and epileptic encephalopathies.
Mario Mastrangelo, Simona Petrucci, Giuliana Lentini, Marco Fabiani, Maria Piane, Francesco Pisani   +5 more
wiley   +1 more source

Predictors of suicide attempt among subjects who were previously exposed to sexual abuse. [PDF]

Int J Soc Psychiatry
Ferahkaya H, Türker M, Coşkun F, Uzun N, Akça ÖF.   +4 more
europepmc   +1 more source

Luxação coxofemoral recidivante em cães Artropexia coxofemoral

, 1997
José de Alvarenga, Hamilton da Silva Pinto, Regina Suplicy   +2 more
openalex   +1 more source

Safety, tolerability, immunogenicity, and efficacy of ABvac40 active immunotherapy against Aβ40 in patients with mild cognitive impairment or very mild Alzheimer's disease: A randomized, double‐blind, placebo‐controlled phase 2 study

Alzheimer's &Dementia, Volume 21, Issue 10, October 2025.
Abstract INTRODUCTION ABvac40 is an investigational active immunotherapy (vaccine) targeting Aβ40. This study assessed the safety and immunogenicity of ABvac40 in patients with amnestic mild cognitive impairment or very mild Alzheimer's disease. METHODS AB1601 was a multicenter, randomized, double‐blind, placebo‐controlled phase 2 study.
María Pascual‐Lucas, Ana María Lacosta, María Montañés, Jesús Canudas, Jorge Loscos, Inmaculada Monleón, José Antonio Allué, Leticia Sarasa, Noelia Fandos, Judith Romero, Manuel Sarasa, Mireia Torres, Dermot Whyms, Jose Terencio, Gerard Piñol‐Ripoll, Mercè Boada   +15 more
wiley   +1 more source